home.social

#alteogen — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #alteogen, aggregated by home.social.

  1. Yonhap Infomax News @[email protected] ·

    Alteogen secures MFDS approval for Eylea biosimilar Eyzen-F Inj, entering South Korea's aflibercept market following European approval, with Phase 3 trials demonstrating therapeutic equivalence and safety across 12 countries
    #YonhapInfomax #Alteogen #EyleaBiosimilar #EyzenFInj #MFDSApproval #Aflibercept #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #alteogen #eyleabiosimilar #eyzenfinj #mfdsapproval #aflibercept
  2. Yonhap Infomax News @[email protected] ·

    Alteogen secures MFDS approval for Eylea biosimilar Eyzen-F Inj, entering South Korea's aflibercept market following European approval, with Phase 3 trials demonstrating therapeutic equivalence and safety across 12 countries
    #YonhapInfomax #Alteogen #EyleaBiosimilar #EyzenFInj #MFDSApproval #Aflibercept #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #alteogen #eyleabiosimilar #eyzenfinj #mfdsapproval #aflibercept
  3. Yonhap Infomax News @[email protected] ·

    Alteogen secures MFDS approval for Eylea biosimilar Eyzen-F Inj, entering South Korea's aflibercept market following European approval, with Phase 3 trials demonstrating therapeutic equivalence and safety across 12 countries
    #YonhapInfomax #Alteogen #EyleaBiosimilar #EyzenFInj #MFDSApproval #Aflibercept #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #stockmarket #bonds #securities #banking #financialmarkets #economics
  4. Yonhap Infomax News @[email protected] ·

    Alteogen secures MFDS approval for Eylea biosimilar Eyzen-F Inj, entering South Korea's aflibercept market following European approval, with Phase 3 trials demonstrating therapeutic equivalence and safety across 12 countries
    #YonhapInfomax #Alteogen #EyleaBiosimilar #EyzenFInj #MFDSApproval #Aflibercept #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #alteogen #eyleabiosimilar #eyzenfinj #mfdsapproval #aflibercept
  5. Yonhap Infomax News @[email protected] ·

    Alteogen Inc. reported a 275% year-on-year surge in 2023 operating profit to 1.148 trillion won, with revenue more than doubling, reflecting robust growth in South Korea's biopharmaceutical sector.
    #YonhapInfomax #Alteogen #OperatingProfit #Revenue #Biopharmaceutical #YearOnYearGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #alteogen #operatingprofit #revenue #biopharmaceutical #yearonyeargrowth
  6. Yonhap Infomax News @[email protected] ·

    Alteogen Inc. reported a 275% year-on-year surge in 2023 operating profit to 1.148 trillion won, with revenue more than doubling, reflecting robust growth in South Korea's biopharmaceutical sector.
    #YonhapInfomax #Alteogen #OperatingProfit #Revenue #Biopharmaceutical #YearOnYearGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #alteogen #operatingprofit #revenue #biopharmaceutical #yearonyeargrowth
  7. Yonhap Infomax News @[email protected] ·

    Alteogen Inc. reported a 275% year-on-year surge in 2023 operating profit to 1.148 trillion won, with revenue more than doubling, reflecting robust growth in South Korea's biopharmaceutical sector.
    #YonhapInfomax #Alteogen #OperatingProfit #Revenue #Biopharmaceutical #YearOnYearGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #stockmarket #bonds #securities #banking #financialmarkets #economics
  8. Yonhap Infomax News @[email protected] ·

    Alteogen Inc. reported a 275% year-on-year surge in 2023 operating profit to 1.148 trillion won, with revenue more than doubling, reflecting robust growth in South Korea's biopharmaceutical sector.
    #YonhapInfomax #Alteogen #OperatingProfit #Revenue #Biopharmaceutical #YearOnYearGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #alteogen #operatingprofit #revenue #biopharmaceutical #yearonyeargrowth
  9. Yonhap Infomax News @[email protected] ·

    Alteogen, a South Korean biopharmaceutical company, reported a 275% year-on-year jump in 2023 operating profit, reaching KRW 114.8 billion.
    #YonhapInfomax #Alteogen #OperatingProfit #2023Earnings #Biopharmaceutical #KRW1148Billion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #alteogen #operatingprofit #2023earnings #biopharmaceutical #krw1148billion
  10. Yonhap Infomax News @[email protected] ·

    Alteogen, a South Korean biopharmaceutical company, reported a 275% year-on-year jump in 2023 operating profit, reaching KRW 114.8 billion.
    #YonhapInfomax #Alteogen #OperatingProfit #2023Earnings #Biopharmaceutical #KRW1148Billion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #alteogen #operatingprofit #2023earnings #biopharmaceutical #krw1148billion
  11. Yonhap Infomax News @[email protected] ·

    Alteogen, a South Korean biopharmaceutical company, reported a 275% year-on-year jump in 2023 operating profit, reaching KRW 114.8 billion.
    #YonhapInfomax #Alteogen #OperatingProfit #2023Earnings #Biopharmaceutical #KRW1148Billion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #stockmarket #bonds #securities #banking #financialmarkets #economics
  12. Yonhap Infomax News @[email protected] ·

    Alteogen, a South Korean biopharmaceutical company, reported a 275% year-on-year jump in 2023 operating profit, reaching KRW 114.8 billion.
    #YonhapInfomax #Alteogen #OperatingProfit #2023Earnings #Biopharmaceutical #KRW1148Billion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #alteogen #operatingprofit #2023earnings #biopharmaceutical #krw1148billion
  13. Yonhap Infomax News @[email protected] ·

    Global pharmaceutical firms are paying upfront to secure technology transfer deals with Alteogen, as demand for its subcutaneous injection platform surges; Shinhan Investment maintains a 730,000 won target price, citing strong licensing prospects despite recent patent litigation.
    #YonhapInfomax #Alteogen #TechnologyTransfer #ShinhanInvestment #OptionAgreement #TargetPrice730000Won #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #alteogen #technologytransfer #shinhaninvestment #optionagreement #targetprice730000won
  14. Yonhap Infomax News @[email protected] ·

    Global pharmaceutical firms are paying upfront to secure technology transfer deals with Alteogen, as demand for its subcutaneous injection platform surges; Shinhan Investment maintains a 730,000 won target price, citing strong licensing prospects despite recent patent litigation.
    #YonhapInfomax #Alteogen #TechnologyTransfer #ShinhanInvestment #OptionAgreement #TargetPrice730000Won #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #alteogen #technologytransfer #shinhaninvestment #optionagreement #targetprice730000won
  15. Yonhap Infomax News @[email protected] ·

    Global pharmaceutical firms are paying upfront to secure technology transfer deals with Alteogen, as demand for its subcutaneous injection platform surges; Shinhan Investment maintains a 730,000 won target price, citing strong licensing prospects despite recent patent litigation.
    #YonhapInfomax #Alteogen #TechnologyTransfer #ShinhanInvestment #OptionAgreement #TargetPrice730000Won #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #stockmarket #bonds #securities #banking #financialmarkets #economics
  16. Yonhap Infomax News @[email protected] ·

    Global pharmaceutical firms are paying upfront to secure technology transfer deals with Alteogen, as demand for its subcutaneous injection platform surges; Shinhan Investment maintains a 730,000 won target price, citing strong licensing prospects despite recent patent litigation.
    #YonhapInfomax #Alteogen #TechnologyTransfer #ShinhanInvestment #OptionAgreement #TargetPrice730000Won #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

    #yonhapinfomax #alteogen #technologytransfer #shinhaninvestment #optionagreement #targetprice730000won